Development of an adenosquamous carcinoma histopathology – selective lung metastasis model

• DOI: 10.1242/bio.059623
• Publication Date: 2022-11-10T16:49:05Z
• Authors: Iris A. K. Lähden...; Jennifer R. Devlin; Ashwini S. Nagaraj; Sarang S. Talwelkar; Jie Bao; Nora Linnavirta; Ceren Şeref Vujak...; Elina A. Kiss; Annabrita Hemmes; Emmy W. Verschuren
• Keywords: 0303 health sciences; lung colonization; Lung Neoplasms; QH301-705.5; Science; adenosquamous carcinoma; Q; Adenocarcinoma; 3. Good health; ErbB Receptors; Biomedicine; Carcinoma, Adenosquamous; 03 medical and health sciences; Carcinoma, Non-Small-Cell Lung; histopathology; Carcinoma, Squamous Cell; Tumor Microenvironment; metastasis; Humans; Biology (General); Cancers; preclinical model; nsclc; Research Article

ABSTRACT Preclinical tumor models with native tissue microenvironments provide essential tools to understand how heterogeneous tumor phenotypes relate to drug response. Here we present syngeneic graft models of aggressive, metastasis-prone histopathology-specific NSCLC tumor types driven by KRAS mutation and loss of LKB1 (KL): adenosquamous carcinoma (ASC) and adenocarcinoma (AC). We show that subcutaneous injection of primary KL; ASC cells results in squamous cell carcinoma (SCC) tumors with high levels of stromal infiltrates, lacking the source heterogeneous histotype. Despite forming subcutaneous tumors, intravenously injected KL;AC cells were unable to form lung tumors. In contrast, intravenous injection of KL;ASC cells leads to their lung re-colonization and lesions recapitulating the mixed AC and SCC histopathology, tumor immune suppressive microenvironment and oncogenic signaling profile of source tumors, demonstrating histopathology-selective phenotypic dominance over genetic drivers. Pan-ERBB inhibition increased survival, while selective ERBB1/EGFR inhibition did not, suggesting a role of the ERBB network crosstalk in resistance to ERBB1/EGFR. This immunocompetent NSCLC lung colonization model hence phenocopies key properties of the metastasis-prone ASC histopathology, and serves as a preclinical model to dissect therapy responses and metastasis-associated processes.